Presage Biosciences and Millennium: The Takeda Oncology Company Enter Into Cancer Research Agreement

Published: Apr 06, 2012

SEATTLE, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Presage Biosciences, a leader in identifying clinically viable oncology drug combinations, today announced that it has entered into a cancer research agreement with Millennium: The Takeda Oncology Company. The research agreement will provide Millennium with access to Presage’s proprietary technology platform to enable non-clinical identification of effective novel oncology drug combinations in solid tumors.

Back to news